Home / Transcripts / ALK-Abelló A/S (ALKB) · February 20, 2026

ALK-Abelló A/S (ALKB) Earnings Call Transcript

February 20, 2026

Nasdaq Copenhagen DK Health Care Pharmaceuticals earnings 48 min

Earnings Call Speaker Segments

Per Plotnikof executive
#1

Good day, and welcome to ALK's presentation of the Q4 and full year 2025 results. I'm Per Plotnikof, Head of Investor Relations, and thanks to all of you for being here. On slide two, I'll go over who is speaking and the agenda for today's call. Joining me are CEO Peter Halling and CFO Claus Steensen Sølje. Peter and Claus will take you through the Q4 and full year highlights, trends in the market and products, and the financial performance for the full year. After that, we'll give you an update on strategic progress and priorities, and then present our outlook for 2026. As always, we'll finish with a Q&A session. To get us started, I'll turn things over to Peter and slide number three. Please go ahead, Peter.

Peter Halling executive
#2

Thank you, Per, and thanks to everyone for being on this call. We turned in a strong fourth-quarter performance, which brought us to close 2025 right at the upper bound of our most recent guidance. To begin, I'd like to point to three important strategic advances made during the quarter. First, the pediatric launch of our house dust mite and tree pollen tablets, ACARIZAX and ITULAZAX, gives prescribers in key markets broader access and carried on performing at a very high level. Second, the European rollout of EURneffy, or simply neffy, is ongoing. After our first launch in Germany in late June, EURneffy had reached an 18% value share in Germany by the end of 2025. We have since also launched in the UK, and by year-end, market access was likewise secured in Greece, Denmark, and Slovenia, with launches anticipated soon. Although we remain in the early stages, the first market reaction to neffy backs the product's potential over the long term. At the same time, established clinical practice still leans toward conventional anaphylaxis therapies, and we will keep working closely with the medical communities to encourage adoption. Very recently, in late January, we obtained a positive opinion from the European authorities for approval of the 1 mg version of EURneffy for emergency treatment of anaphylaxis in children weighing 15 to 30 kg.

Peter Halling executive
#3

Third, we're still seeing solid progress in both our established and newer partnerships across China, Japan, and the US — both on execution and on getting more activities ready for 2026. Those developments will be covered later in the slides. Moving now to the financials: Q4 revenue rose 17%, powered by strong results in every geography, with tablets in Europe and anaphylaxis as the main drivers. EBIT was up 88% at a 22% margin, in line with expectations, reflecting ongoing strategic investments in commercial initiatives that support future growth and innovation across markets. With that, I'll turn to the full year picture on slide four. 2025 was a landmark year for ALK, and we clearly beat our initial expectations for financial performance. Revenue climbed 15% in local currencies to 6.3 million DKK, which is $1 billion, fueled by double-digit growth across our sales regions. Importantly, we're proud to have also reached our long-standing target of 25 in '25. That's a big achievement for the company — a 25% EBIT margin, and 26% last year. Let me highlight three full year milestones. The commercial momentum rested on a solid expansion of our patient base. We treated 500,000 more patients in '25, so a total of 3.1 million patients are now treated with ALK's products.

Peter Halling executive
#4

This became achievable thanks in no small part to our tablet business continuing to grow. To illustrate, launching ACARIZAX and ITULAZAX for children contributed to a wider patient inflow and greater uptake throughout the tablet portfolio. In anaphylaxis — ALK's primary growth engine last year — we additionally recorded a positive contribution from EURneffy, which reflects ALK's portfolio strategy. Notably, that aligns with the strategic course we have pursued since 2024. Central to delivering on Allergy+ is enlarging the addressable market and extending patient reach, particularly via pediatric indications, while also drawing on partnerships so that even more patients can be helped. By way of illustration, in China we have completed the handover of sales and marketing activities to GenSci, our new partner. Simultaneously, we are making our profitability even stronger. EBIT rose by 53%, and the EBIT margin climbed to 26%, underpinned by greater sales, an enhanced gross margin, and disciplined cost control. This likewise represents fulfilment of our 25 in '25 ambition and cements our pledge to hold an EBIT margin at roughly 25% as we keep investing in our ongoing growth. Heartened by such strong momentum, the Board of Directors proposes a dividend of 355 million Danish kroner for '25, equal to 30% of net profit after tax, consistent with our capital structure and long-term ambitions.

Peter Halling executive
#5

With that said, Claus, I'll turn things over to you for the market review on slide 5.

Claus Steensen Sølje executive
#6

Thank you, Peter. To begin, we'll review how each of our sales regions performed, and after that we'll go through the individual product groups. Starting with Europe: Europe was still our biggest region, accounting for 71% of group revenue. We recorded 14% growth that was broad-based across the portfolio and across geographies, including in our largest markets, Germany and France. Demand was solid, and market conditions were mostly stable. Tablets drove most of the growth, rising 19%. Volumes went up, particularly thanks to a healthy inflow of new house dust mite patients on ACARIZAX, helped by the buildup of patients who had begun on grass pollen tablets in earlier years. The new pediatric indications for ACARIZAX, along with our tree pollen treatment ITULAZAX, also contributed positively to growth. On the whole, ACARIZAX and ITULAZAX were the largest contributors, while GRAZAX, our grass treatment, kept growing steadily. Performance was especially strong in Central Europe, including Germany, France, and a number of Eastern European countries, as well as the UK. In the UK, we kept making progress on market access for our key tablet products. ACARIZAX and ITULAZAX became the first AIT tablet treatments admitted to the National Health Services, or NHS, systems with general reimbursement. That's an important step in what has historically been a low-penetrated AIT market.

Claus Steensen Sølje executive
#7

We are currently in the process of broadening those approvals to cover children, and at the same time we're moving forward on making GRAZAX accessible through the NHS. Another point worth mentioning is that unlike 2024, price changes had only a limited effect during 2025. During this year, wholesaler trading dynamics across Europe had just a slight effect on tablet sales. Sales of SCIT and SLIT-drops together rose modestly, by 3%. SLIT-drops kept gaining from an expanding base of prescribers and patients in France, whereas SCIT was somewhat quieter. In our key SCIT markets, Germany and the Nordics, patient initiations were affected to some degree by patients opting for tablets rather than SCIT for the indications our tablet portfolio covers. Lastly, anaphylaxis and other products posted strong growth of 34%, powered by Jext through solid execution, tender wins in Southern Europe, and supply problems at competitors. We additionally recorded a positive, though modest, contribution from the first EURneffy launches in Europe. That growth further highlights how valuable a portfolio approach is in anaphylaxis. Moving on to North America, revenue there returned to growth in 2025, rising 19%, powered by tablets along with anaphylaxis and other products. The US legacy business bounced back from last year's stagnation, with growth powered by ongoing adoption among existing allergy prescribers and, to a small degree, uptake among pediatric prescribers.

Claus Steensen Sølje executive
#8

Canada kept up a stronger pace of expansion. Tablets stayed the primary product line there, and that increase came from solid underlying demand, helped along by the children indication for the house dust mite and tree tablets. Revenue from anaphylaxis and other products rose 34%, which was driven by cost compensation from ARS Pharma tied to co-promotion of neffy in the US, along with stronger sales of life science products as we keep adding customers on our higher-margin solutions. Now let's move to international markets. Revenue there was up 16%. Tablet revenue grew 8%, with smaller markets throughout the Middle East, Southeast Asia, and India continuing to contribute positively, while Japan revenue was affected by shipment phasing, particularly during the second half of the year. In-market demand in Japan stayed strong, and our partner Torii, now part of Shionogi, kept growing sales at a double-digit rate, though capacity constraints continued to hold back its ability to fully satisfy demand for CEDARCURE tablets. With a new facility having recently come online, we expect Torii to be able to supply greater volumes to the market with increasing frequency. China is still the biggest SCIT market in the region, and revenue rose as we keep normalizing shipments after our import license was renewed.

Claus Steensen Sølje executive
#9

In China, in-market sales kept climbing at a double-digit rate as well, helped by the continued growth of the prescriber base at hospitals. Let's now move to slide six for a quick update on the product lines. Tablet sales rose 17% in 2025, which further cements tablets as our main revenue stream. That growth came mostly from an expanding patient base, primarily in Europe and Canada, with pediatric launches of ACARIZAX and ITULAZAX adding momentum, as I mentioned earlier. All in all, the count of new patients beginning tablet treatment rose well above 10% over the year, a good sign for continued solid growth in 2026. SCIT and SLIT-drops posted 5% sales growth for the year, reflecting resumed shipments to China, partly offset by the conversion to tablets in Europe that we mentioned previously. Lastly, anaphylaxis and other product sales were up 34%, driven mainly by a 58% rise in anaphylaxis sales. That was chiefly due to higher Jext sales, though neffy contributed to the growth as well. Let's now go to slide seven for the full year financials. Revenue in 2025 grew 15% in local currencies, reaching 6.3 billion Danish kroner. That marks the first time ALK has surpassed 6 billion DKK in annual revenue.

Claus Steensen Sølje executive
#10

This also marks the seventh year in a row of growth, and those results clearly beat what we initially expected — a revenue increase of 9% to 13%. Gross profit rose to 4.2 billion Danish kroner, giving a gross margin of 67%, which is 3 percentage points higher than last year. That significant and extraordinary improvement stemmed from higher sales volume, a more favorable sales mix, and production efficiencies, showing that scale effects are increasingly materializing in the business. Capacity costs were up just 6% in local currencies, reaching 2.6 billion Danish kroner. By comparison, when you exclude the impact of restructuring costs in '24, capacity costs rose by 9%. As planned, R&D expenses rose by 15%, reflecting investments in our pipeline, including the peanut tablet development program, preclinical projects, and the Phase 3 bridging trial with ACARIZAX in China. Sales and marketing costs rose by 3%, and by 6% when adjusting for last year's one-off costs driven by tablet launches and the rollout of neffy, while administrative costs rose modestly. Unlike last year, capacity costs in 2025 did not include any one-off expenses. Operating profit, EBIT, rose to 1.65 billion Danish kroner, and the EBIT margin improved to 26%, up by 6 percentage points from last year.

Claus Steensen Sølje executive
#11

So that means we hit our key profitability milestone — the 25 in '25 EBIT margin target — which we formally established back in 2021, when the EBIT margin was only 4%. We achieved this more than 20 percentage point increase in the EBIT margin while simultaneously making substantial growth investments, which shows disciplined prioritization across the whole organization and directing resources to the growth levers with the greatest impact. Free cash flow came in positive at 1.4 billion Danish kroner, versus negative 204 million DKK in 2024. That improvement reflects both the higher earnings and an upfront payment of 244 million Danish kroner from GenSci. On top of that, 2024 included a 1 billion DKK license payment to ARS Pharma and 150 million Danish kroner tied to the PREPEN acquisition. Investments in 2025 mainly reflected building up capacity for tablet production, upgrades to legacy production, a milestone payment to ARS Pharma linked to the first commercial sales of EURneffy, and other infrastructure investments. That wraps up our operations review of 2025, so let's turn to slide eight for a closer look at how our Allergy+ strategy is being executed. Please go ahead, Peter.

Peter Halling executive
#12

Thanks, Claus. Before we get into how our strategy is progressing, I want to talk about the management change we announced this morning. Henriette Mersebak is stepping down as a member of the Board of Management and as Head of Research and Development. She leaves by mutual agreement, and this is a strategic leadership decision aimed at the long-term needs of the business. We've appointed Henrik Jacobi, who was previously ALK's Head of R&D, as a special advisor to the Executive Leadership Team, reporting to me, and we've begun the search for a new Head of R&D. I want to thank Henriette for what she has contributed over the past 3 years. Together with her team, she secured important regulatory approvals, including for our pediatric treatments, and also moved our peanut allergy program forward, among other achievements. We stay committed to our ambitions across our different therapy areas, and in particular to the development in food allergy as well as other disease areas. Now, turning to our progress in Allergy+, we entered 2025 with a clear focus on launching our respiratory allergy tablets for children, and we have made important strides forward. With the support of the children launches, we grew both our prescriber and patient bases during the year, raising the number of patients treated with ALK's products by around half a million, or 500,000, to an estimated 3.1 million.

Peter Halling executive
#13

Most of that growth — roughly 300,000 — came from tablets, kids and teens included. Tablets continue to be a key growth engine down the road, and we remain on track toward our goal of reaching 5 million people annually by 2030. As of today, the house dust mite tablet — ACARIZAX, or ODACTRA in North America — has pediatric approval in 30 countries and has been launched in 21 of those. Our tree pollen allergy tablet, ITULAZAX, known as ITULATEK in North America, holds approval for children and adolescents in 20 countries and has launched in 13, counting the quite recent Norway launch just a few days back. These rollouts have changed the makeup of our prescriber base. By year-end, over 4,000 prescribers in markets we serve directly had already written one of the two tablets for children, and cross-tablet adoption stayed strong. In key European markets, over 90% of pediatric ITULAZAX prescribers also prescribe ACARIZAX. In Germany, along with other countries, pediatricians have become an increasingly significant prescriber group. In the US, we broadened our reach in the pediatric segment through the co-promotion agreement with ARS Pharma. In the UK, NHS admission of ACARIZAX and ITULAZAX with general reimbursement marks an important structural step in an AIT market that has historically been underpenetrated, and work continues to extend access locally.

Peter Halling executive
#14

We also achieved solid progress with our two new partners, GenSci in China and Shionogi in Japan, after their acquisition of Torii in '25. Both partners show a strong commitment to further developing the Chinese and Japanese allergy markets, respectively. Looking ahead to 2026, our key priorities in the respiratory therapy area will be maximizing the value of the tablet portfolio. That means continuing the rollout to children in markets where we've already secured access to prescribers. At the same time, we expect to launch tablets for children in additional markets so that adults, adolescents, and children can all benefit from our treatments, no matter where they live. In anaphylaxis, neffy is a strategic enabler of Allergy+. In 2025, we moved into early commercial execution in Europe and in North America. The co-promotion agreement with ARS Pharma in the US is a lever to expand our market reach and build further insights. For this year, our focus is on succeeding with neffy. We expect 2026 to be a buildup year focused on driving market access and initial rollout. In practical terms, that means continuing market-shaping activities across geographies and patient groups, and building a clear market position that allows us to move from introduction to broader commercial execution.

Peter Halling executive
#15

Our approach here is a combined portfolio one, bringing neffy and Jext together so we can address differing patient and channel requirements while further reinforcing our overall presence in emergency allergy care. Moving on to slide nine. On the food allergy front, we kicked off a Phase 2 clinical trial for our peanut SLIT tablet, and that product has been granted Fast Track designation by the FDA. Topline Phase 2 results remain on schedule for reporting in Q2 of this year. Looking at 2026, our aim is to move the peanut program forward into Phase 3 — provided, naturally, that Phase 2 delivers positive data. Beyond that, we are advancing preclinical programs across new disease areas, and our partner ARS Pharma has launched a Phase 2b trial of neffy for acute flares tied to chronic spontaneous urticaria. We hold the rights to that indication in our territories as well. Lastly, we'll keep investing in our infrastructure so that ALK can be scaled up — that covers spending on tablet production capacity, IT, and AI. Further business development and partnership opportunities will also remain an area we explore. Those could be commercial stage opportunities as well as research stage ones. In short, continued execution defines 2026, and our foundation is a strong one.

Peter Halling executive
#16

ALK is uniquely placed to keep growing for many years ahead, which will benefit a rising number of patients who suffer from severe uncontrolled allergies. With that, Claus, I'll return the floor to you, along with the full-year outlook on slide 10.

Claus Steensen Sølje executive
#17

Thank you, Peter. Looking ahead to 2026, we anticipate carrying on with our pattern of double-digit top-line expansion, while the EBIT margin should stay in line with what we target over the long term. So revenue should rise 11% to 15% at local currencies, with the EBIT margin coming in at roughly 25%. Let me walk you through a few of the key assumptions. We expect organic revenue growth in local currencies in every sales region and across each product group. That growth should mostly come from volume. The bottom of the range mirrors a possible drag from price and rebate changes, chiefly in Europe, plus softer growth in anaphylaxis and SCIT. The top of the range presumes steady price and rebate conditions along with possible upside from tablet and anaphylaxis sales. As always, shipment timing to China and Japan could cause quarter-to-quarter swings. Tablet sales should rise by double digit in all sales regions, powered by further growth of the prescriber and patient bases, and as you would expect, children and adolescents are projected to make up a larger portion of those sales. Anaphylaxis and other product sales should likewise increase by double digit, led by the ongoing commercialization of neffy. Revenue from SCIT and SLIT-drops is expected to grow by single digits, thanks to higher SCIT volumes shipped to China, modest volume gains in Europe for both SCIT and SLIT-drops, and better SCIT pricing in North America.

Claus Steensen Sølje executive
#18

We anticipate a modest decline in gross margin, since the 2025 favorable volume and mix—particularly stronger tablet sales in Europe—will be offset by expansion of partner-related revenue in Japan and China at lower margins, along with rising neffy sales, which likewise carry lower margins. We expect production efficiencies, less scrapping, and procurement savings to largely offset inflation. The capacity cost to revenue ratio should stay unchanged, as we will reinvest the gains from increased scale into key strategic growth opportunities. R&D expenses are planned to rise but remain at roughly 10% of revenue. Sales and marketing expenses should increase, while administrative costs are planned to come down slightly. Lastly, free cash flow is expected to be positive at 800 million to 1 billion DKK. CapEx is projected at approximately 500 million DKK, focused on production capacity, expansion, and IT infrastructure. Potential changes to international tariffs are not expected to materially affect growth or earnings, given our geographical footprint. In summary, we expect 2026 to deliver continued volume-driven organic growth while we keep investing to support our long-term ambitions. With that, I would like to hand it back to you, Per, and slide 11.

Per Plotnikof executive
#19

Thanks, Claus, and thanks, Peter. That brings our presentation to a close, and now we'll move into the Q&A portion. Operator, would you please go ahead?

Operator operator
#20

Thanks. We’re moving into the Q&A portion now. If you’d like to ask something, press star followed by one on your touchtone phone. When you’re on a speakerphone, please lift the handset first before you press those keys. Should your question get answered at any point and you want to pull it, just press star, then two. Right now we’ll take a brief pause while the roster is put together. Our first question is from Thomas Bowers at SEB. Go ahead, please.

Thomas Bowers analyst
#21

Yes, thanks a lot. Hopefully you’re able to hear me — I was having a few audio problems. Can you hear me okay? Sorry about that.

Peter Halling executive
#22

Sort of, Thomas.

Claus Steensen Sølje executive
#23

We’re able to hear you.

Peter Halling executive
#24

Yeah.

Thomas Bowers analyst
#25

Oh, perfect. Great. Thank you very much. First question, just on what level of contribution should we think for the pediatric indications here for your 2026 growth guidance? You say, given the early launch trajectory, any first take here on how we should think about the peak potential here? Then secondly, can you maybe just add a bit of flavor? You did address this in the remarks, but maybe the split here between specialists and pediatricians among those first 4,000 prescribers. How does it look right now with the high volume pediatric prescribers at this point? Any color here will be very helpful to us here. Then lastly, just in regards of the pricing impact or the pricing rebate impact. I understand that France is mostly done deal here. Is that part of your sort of mid-point growth guidance? How should we actually think about the impact when you look at sort of the competitive situation in France? Are we looking at potentially even sort of a price parity here on the SLIT-drops and tablets? I guess the question here is whether there may be some sort of any dynamics that could give you any potential competitor headwinds or tailwinds in France in the wake of this price adjustments.

Thomas Bowers analyst
#26

Yeah, thanks a lot.

Peter Halling executive
#27

Yeah. Thomas, Peter. I believe we got all of them. I'll begin, and I'll also have Claus and Per come in. Let me start with the peds contribution and the peds potential. I know that last year we provided an indication of 1% to 2% from the peds and the 1% on neffy, or less than 1% on neffy, and then we upgraded. We're not guiding on this, but what we can say is that we expect it to be higher given the continued positive progression of the business. Then you cut out a little bit, if I'm not answering your second question 100% correctly, the specialist versus peds question. I think based on what we're seeing is obviously, as we also mentioned here with the 4,000, that this is a new development, which is positive. I do think that what's important and where we're also learning is where allergists are fully focused on allergies, then do remember pediatricians are treating a multitude of diseases and different types of patients. Even though we see a good progression, and we talk typically around 25,000 prescribers normally, then with the pediatricians on top, it's not a one-to-one.

Peter Halling executive
#28

Clearly, we're quite optimistic that this will keep going and that the interest remains, since that provides the prescriber growth in the future that lets us do more for children as we move ahead. If my answer wasn't complete, please ask again. Last, on pricing, I'll hand it to Claus. I can address the final piece regarding the competitive side. We don't really make comments about that. Clearly, there's also a rebalancing happening in the French market, which we think is, on balance, making things more straight. That's all we can say at this point. Perhaps you'd like to discuss the impact further.

Claus Steensen Sølje executive
#29

Yes, I can do that. Thomas, thank you for those questions. On pricing, regarding what's baked into our midpoint or our guidance: you're correct that the French price reduction we observed late last year and early this year, '26, had a really big impact on us that wasn't sustainable, you might say, and we've factored that into this year's guidance. As for rebates, particularly at the lower end of the guidance range, it's very much the German rebate, of course. There can be other smaller ones elsewhere around the world, especially in Europe, but naturally the big one in Germany is what can really hit us. Yes, the French price is included in the guidance. That's

Thomas Bowers analyst
#30

That's great. Thanks so much.

Peter Halling executive
#31

Alright.

Operator operator
#32

Benjamin Jackson from Jefferies has the next question. Your line is open.

Benjamin Jackson analyst
#33

Thanks. Appreciate the question, guys. I suppose my first one concerns peanut allergy. We're clearly getting nearer to topline results from that study. What ought we to expect from you regarding how this gets communicated? Will you give us any specifics when the headline comes out? And beyond merely looking for the actual signal in this study, what else are you after? Are you attempting to hit some internal threshold in order to move it forward, or is a good signal on its own sufficient for you to keep exploring it? That's my first question. Second, backing off that a bit, respiratory tablets have obviously been somewhat tricky in the US, given the dynamics there. How should we think about a possible food allergy tablet in the US, and what could be done to better establish that market there? Then third and last, I imagine the answer is quite short, but can you offer any further commentary on the potential for neffy in CSU in your regions? Obviously, your partner has spoken quite openly about how large they view that opportunity. How are you seeing it?

Benjamin Jackson analyst
#34

Would you be willing to back that, and possibly even put money behind it too? Of course, there's no obligation to do so, but we'd love to hear any thoughts you have on that. Thanks.

Peter Halling executive
#35

Thank you, Benjamin. That's great. Per, would you handle the first question about communication, and I'll take the final two.

Per Plotnikof executive
#36

Yes. Thank you, Ben. Regarding communication, here's what to expect on our comms side when topline results arrive later in the second quarter of this year: since we view this as material for us, we'll issue a separate company announcement on the news just to confirm that. Naturally, once we look into the data, we'll aim to provide as complete and meaningful a picture as possible after we've worked through those topline results. Then, naturally, the ultimate aim of this study and its results is to establish a clear proof of concept for the peanut tablet and to guide our decisions on the design of the Phase 3 study. That means which exact dose we'll go with, what the treatment regimen will look like, the uptitration schemes, and potentially also the treatment duration we see in the maintenance phase, etc. There'll be a lot of information. Obviously, also the safety profile of the drug — sorry, I forgot that. There'll be a lot of information we can draw out of this Phase 2. Naturally, that will inform our Phase 3 plans, such that in the best of all worlds, we can initiate at the end of this year and then have results read out maybe in '28 and then with a submission that year and hopefully an approval late '29 and then launch and roll out into the 2030s.

Per Plotnikof executive
#37

Hopefully that clears that up. Peter, I'll hand things over to you.

Peter Halling executive
#38

Alright, thanks, Per. Benjamin, regarding your question about respiratory tablets and how they compare with US peanut, I think first of all these are two distinct ways of viewing the situation. You need to consider the economics for the prescribers behind the products, and also that for the tablets, an alternative treatment exists today, whereas a US peanut tablet will prioritize patient needs above all, while also examining how we make it appealing to prescribers as well. Then thirdly on that point, bear in mind that alternatives are truly scarce, and those already on the market differ, both regarding treatment regimes and potentially also in terms of patient pool, and so on. This is a completely different way of approaching it. Instead of focusing on the modality or the technology, if you like, whether it's an injection or a tablet, look at the patient pool, the prescriber pool, the economics, and the updosing of the tablets. I just want to ensure that is clear. That covers the US. Put simply, to keep it quite clear, we believe the potential for tablets among allergists, or with allergists, remains quite intact, and it is broad-based rather than a subgroup.

Peter Halling executive
#39

It's broad-based. Then there was a question regarding neffy and CSU. We see the numbers too, and obviously we're excited about what everyone else is getting to see as well. I'd just add a note of caution, since this is a very new market that still needs to be developed. What we do see, and where we agree with the analysis that's out there, is that we do see the patient population, and we do see the need. I think that's very important. There are major differences both in how products are treated and used in the US versus in Europe. Emergency room treatment, the cost of an emergency room visit in the US versus Europe, etc. There are some differences there, and we need to understand that better. Moreover, and importantly, we need to understand what the product would look like, what the final profile of the product is going to be, how it's going to work with patients, and what kind of impact it will have on patients. We need to understand that, and that's going to tell us what price points we potentially can get and how many patients we can actually reach. We're still doing all of that diligence.

Peter Halling executive
#40

To boil it down once more, the opportunity we see in the market strikes us as quite interesting and pertinent to our business, though there are still plenty of things for us to learn before we're able to judge just how large this will become for ALK.

Benjamin Jackson analyst
#41

I really appreciate it.

Operator operator
#42

Jesper Ingildsen from DNB Carnegie has the next question. Go right ahead.

Jesper Ilsøe analyst
#43

Yes, hello, and thank you for allowing me to ask a few questions. Perhaps first on peanut, though it would also be interesting to hear how you view the recent developments in that space, alongside GSK's acquisition of unclear and Stallergenes removing Palforzia from the market, and whether this alters your perspective on the opportunity. Second, regarding the Head of R&D's departure, perhaps a little more detail there on what has led to it. I suppose there could be some concerns about this happening right before the peanut readout in Q2. Conversely, I also understand it may relate more to the longer-term pipeline. I would be interested in getting a sense of what specifically in the long-term pipeline we are talking about here in terms of seeking a different profile. Then perhaps lastly, on neffy. You highlighted that you believed you had captured roughly 18% market share in value in Germany at the end of '25. I would just be curious to hear what you have seen in volume terms, and also whether you have seen any negative impact, such as cannibalization, on Jext in Germany specifically, but also overall for neffy, what kind of growth contribution you expect in '26.

Jesper Ilsøe analyst
#44

Appreciate it.

Peter Halling executive
#45

Yes. Thank you, Jesper, for those questions. I believe they all wound up coming to me. I'll begin with a comment about peanut. Clearly, above all, it's genuinely encouraging to witness such strong interest in food allergies, or concerning food allergies. Regarding GSK-Aiolos specifically, it's plainly a favorable development for us that a firm of GSK's stature is showing interest in this area and is also buying a biologic such as unclear, which largely competes with Xolair. On the price point, I'm not able to comment, but clearly, at more than 2 billion, I think it conveys a signal — that's my own personal view — it conveys a signal that they regard this market as quite interesting. That's an encouraging sign for us. Once again, as I think we've stated throughout, we welcome competition. Keep in mind that different pockets and different categories of patients are served by the various products, and the same holds for DBV. I think that matters. We view the DBV progress as a positive. Then we're beginning to see the market being built, including for toddlers, and so on. You'll also observe, when you examine the data, that there's actually a fairly broad spread of data points out there, including with respect to efficacy, which we likewise find interesting.

Peter Halling executive
#46

Now regarding Palforzia — it has been withdrawn from the market. I believe it was no secret that at first it was struggling, and then Nestlé acquired it, and for reasons unknown to us, they basically determined that things in the market weren't working out as planned, so they decided to pull it. I don't think we can add much beyond that, other than the fact that we don't see this as an issue of market potential. It relates specifically to Palforzia. I believe that concerns the peanut allergy. The food allergy space is a genuinely interesting market with plenty of opportunity, and I think there is more for us to do there. Then you asked about Henriette. Again, just to be very clear, I also told the media this, I think the key point here is that this is a mutual agreement. This is good timing, or the best possible timing. There's never good timing for any of these things, but we are in a good position with our short-term pipeline. We believe we've made good progression, both with the regulatory approvals we've had, but also in terms with Allergy+ overall, peanut, etc.

Peter Halling executive
#47

We do believe — and this is also what we stated at the Capital Markets Day — that looking ahead, ALK wants to have a presence in a wider range of therapy areas: food, anaphylaxis, respiratory, and potentially new ones such as urticaria. Part of that will also involve partnerships and BD&L. That is where we believe, since we have a very strong R&D organization and we believe we have a solid early-stage pipeline, which we also have good control over and where Henriette has been a major contributor, that when we look ahead into the '30s as well, there's an opportunity to further strengthen some of these activities. That is why we've said this is a good moment to seek a profile that may have tried some of these activities in the past and could fit well with ALK. Nothing about Henriette's performance otherwise, because we are happy with where we stand. I think that's the best answer I can give you on that one. Then you asked about neffy and the 18% value share in Germany. Obviously, as in any other market, you see the swings depending on the season. Germany is slightly different from some of the other markets.

Peter Halling executive
#48

The venom segment is a bigger part of that market, which is a good thing in itself, while markets such as the UK, US, and Canada lean more toward food allergy. It has been encouraging for us that the combination of food and venom in Germany got us to that 18% value share quite fast. On volume share in the market, we're at roughly 11%, 12%, and digital efforts are the main thing behind that, which we also see as a positive and interesting sign. Hopefully that covers most of what you asked, Jesper.

Jesper Ilsøe analyst
#49

Yes. That works perfectly. Thanks.

Operator operator
#50

Our following question is from Sushila Hernandez at Van Lanschot Kempen. You have the floor.

Sushila Hernandez analyst
#51

Yes, thanks for taking my questions. I’d appreciate a little more detail on ALK-014. Is it intended for IgE-mediated food allergies? Also, what stage is this asset at in preclinical development, and when might it potentially enter the clinic? And perhaps tying back to the earlier question, what kind of profile are you seeking for your new Head of R&D? Thank you.

Peter Halling executive
#52

Yeah. Thanks. Per, would you take the ALK-014 question? Yep.

Per Plotnikof executive
#53

The ALK-014 program is at an early stage and is currently in preclinical development. Here we're working with a different modality — what we're working with is a fusion-like antibody protein. To put it in context, it acts upstream in the immune cascade. A different modality, a biologic, still early stage, but we do expect that if all goes well, over the next 1 to 2 years this could move forward into clinical development should everything work out. That's the status of it. It's also a different approach from our historic programs, which have all been allergen-specific. This one is allergen-agnostic. Here, it's also a molecule that potentially could be used across multiple indications if all goes well. At present, we're investigating it in food allergy, but we're also looking into other indications that aren't disclosed at this stage. More on that later. A super exciting program, but still early.

Peter Halling executive
#54

Yeah. Thanks, Sushila. So again, regarding Henriette, I believe I covered most of that when Jesper asked. What we're after is a profile that has explored the partnership BD&L space more broadly, and also someone able to complement our wider allergy portfolio. Essentially, you could say Henriette contributed a great deal of experience in the preclinical area. We hold plenty of strong competencies there. Our view is that the organization and R&D overall could gain from a profile who has tried some of these other areas. Nothing dramatic in that respect, and it's simply a good moment for a potential change. That's essentially the background. Also, please note that Henrik Jacobi will be assisting ALK as a special advisor, helping us keep advancing the internal pipeline as well. I think we're in a good position. I hope that answered your question, Sushila.

Sushila Hernandez analyst
#55

Yes. Thanks. That's clear.

Operator operator
#56

Just a quick reminder — if you'd like to ask a question, press star followed by one to get into the question queue. Our next question is from Thomas Bowers at SEB. Go ahead, please.

Thomas Bowers analyst
#57

Yes, thank you so much for taking a few follow-ups. I have a quick question about tablet sales in international markets. Of course, I understand the phasing, the quarterly phasing here, but how should we look at at least Q1 and Q2 here, and how much actually still depends on this Shionogi takeover, completing the transfer here? Of course, coming off a rather weak Q4, are we going to see a bigger number here in Q1? That's the first question. Then just on the gross margin outlook, of course, I understand the mixed effect year-over-year, but are you still seeing an underlying improvement here also in '26? Maybe you can address what magnitude we're looking at here. Then the last question, just on neffy. I understand the 18% market share here in Germany, that's quite impressive, I think. Is there anything specific driving this? Also with regard to Canada, you're seeing a sort of a delay here. I'm not sure whether you expect this to come through here in the first half, but is there sort of a risk here that you will miss the back-to-school season? Or is that mainly the US that is dependent on that compared to Canada?

Thomas Bowers analyst
#58

I appreciate it.

Peter Halling executive
#59

Appreciate that, Thomas. International markets and gross margin will be handled by Claus, while I’ll talk about neffy. Over to you, Claus.

Claus Steensen Sølje executive
#60

I will. Thomas, Thomas. Regarding international markets and the growth we're observing there, you shouldn't anticipate a meaningful effect in the first half of '26. That applies both to what you witnessed last year in '25 and to the situation here in '26. The larger growth contribution from shipments in the international market, Japan and China, is something you should expect to arrive in the second half of '26. That's where you'll see the meaningful effect coming through. Don't expect — there will still be shipments, no doubt about that — but from a growth standpoint, don't expect a big effect in the first half. It will come in the second half. If I then move to gross margin, just to go a bit further into the helicopter, then yes, we had this 64% last increase from 64% to 67%, quite significant and extraordinary compared with what we have normally seen in gross margin. Our aim is to get this 1 percentage point year-in-year improvement, and that's in our plans. Because of the product mix, and especially how we have sold tablets and the higher sales of tablets, particularly in Q4 than what we had expected, but also this with the quarterly shipments between the international markets there and our partners, we saw this extraordinary jump in our gross margin.

Claus Steensen Sølje executive
#61

Like we've mentioned several times in connection with the most recent quarterly announcement, you should then anticipate a modest decline in '26 compared with '25. That's mainly because of higher sales from the partnerships. When we do this with Torii, now Shionogi, and then GenSci in China, plus, of course, the growth of our neffy with ARS, all of that comes at a lower gross margin. Because that represents a bigger share of our total sales, it will drag the gross margin down. You could say there's nothing tied to how the underlying gross margin is developing. That remains positive, and we're still focused on improving yield and cutting scrap and so forth, and we expect that to keep going. In '26, it's mainly product mix that will weigh on the gross margin, so to speak. I hope that clears it up.

Thomas Bowers analyst
#62

Yeah.

Peter Halling executive
#63

On the neffy question and these markets—let me address that. Clearly, neffy's capacity to capture an 18% value share of the market has positively surprised us. Keep in mind—I believe we mentioned this previously too—that Germany is usually a smaller market, and it differs somewhat from other markets on both the reimbursement side and the payer side. That naturally gives us hope, particularly since the makeup of prescribers in Germany involves general practitioners and so on. That isn't quite what you'd typically anticipate, which in this instance is a good thing. Turning to the UK and Canada: for the UK, it's really a matter of securing formulary access across all 42 regions. That's where the hard work lies. We do believe that once it's on formulary and things get going, it will become a growth driver for the company. We don't expect this to happen as quickly as one might wish. It takes time, since it's a public process. Is there an issue related to back-to-school? We don't know in that regard, but we've budgeted conservatively around it, and we don't view back-to-school as a major issue. Naturally, we'd like to see uptake and an effect from back-to-school, but we aren't betting everything on it, because we're realistic about that as well.

Peter Halling executive
#64

In Canada, you've got various provinces, each with their own healthcare systems. We need to secure regulatory approval there. We expect that to come through in Q1. After that, if we're able to launch, we should also be in a position to catch the back-to-school period in Canada. It's also shaping up to be an interesting stretch, since there appears to be somewhat greater willingness to gain some penetration in the Canadian market. Again, that market differs from the UK and Germany. Finally, I'll note that we're still waiting to launch the 1 mg in Europe. That's for smaller children, or children weighing between 15 and 30 kg, so clearly that's another thing we're eager to bring to market. What I'm telling you, Thomas, is that 2026, as we've said before, is a year in which we are building up and will keep building up. We gain the benefit of the full portfolio, but we do hope and expect that neffy will become a growing contributor to the business. I hope that addresses some of your questions and adds some nuance.

Thomas Bowers analyst
#65

That’s quite useful. Thanks a lot.

Operator operator
#66

That wraps up our question-and-answer session. I'd now like to hand the conference back for any closing remarks.

Per Plotnikof executive
#67

Thanks, and thanks everyone for those solid questions. Before we wrap up, I’ll simply point out our forthcoming events and financial calendar, which you’ll find on slide number 12, and we look forward to seeing you soon—whether that’s in Copenhagen, London, Paris, or the US. As ever, feel free to reach out to us should you have any further questions. That brings today’s session to a close, and thank you all for being with us. Goodbye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete ALK-Abelló A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to ALK-Abelló A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.